We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+26.13%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.02B
AUM Growth
+$18.4M
Cap. Flow
-$139M
Cap. Flow %
-6.88%
Top 10 Hldgs %
53.81%
Holding
65
New
13
Increased
7
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$47.8M
2
NKTX icon
Nkarta
NKTX
+$43.3M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$19.6M
4
KURA icon
Kura Oncology
KURA
+$19.4M
5
ALLO icon
Allogene Therapeutics
ALLO
+$16.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$188M
2
IMGN
Immunogen Inc
IMGN
+$87.8M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$79.1M
4
ARGX icon
argenx
ARGX
+$23.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.57M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
26
Viking Therapeutics
VKTX
$4.28B
$24.6M 1.22%
+300,000
New +$13.3M
ORIC icon
27
Oric Pharmaceuticals
ORIC
$1.1B
$23.8M 1.18%
1,732,571
– –
KURA icon
28
Kura Oncology
KURA
$960M
$21.3M 1.05%
+1,000,000
New +$19.4M
GERN icon
29
Geron
GERN
$917M
$19.8M 0.98%
6,000,000
+3,000,000
+100% +$6.72M
DAWN
30
DELISTED
Day One Biopharmaceuticals
DAWN
$19.7M 0.97%
1,189,943
– –
THRD
31
DELISTED
Third Harmonic Bio
THRD
$18.9M 0.93%
2,000,000
+1,250,000
+167% +$12.2M
KALV
32
DELISTED
KalVista Pharmaceuticals
KALV
$18.9M 0.93%
1,590,000
-60,000
-4% -$800K
ALLO icon
33
Allogene Therapeutics
ALLO
$614M
$17.2M 0.85%
+3,850,000
New +$16.1M
GPCR icon
34
Structure Therapeutics
GPCR
$3.3B
$17.1M 0.85%
400,000
– –
PRTA icon
35
Prothena Corp
PRTA
$449M
$17.1M 0.84%
690,000
+25,000
+4% +$744K
SANA icon
36
Sana Biotechnology
SANA
$868M
$15.4M 0.76%
+1,545,000
New +$11.6M
RLAY icon
37
Relay Therapeutics
RLAY
$4.23B
$15.1M 0.75%
1,819,132
– –
PSTX
38
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$14.3M 0.71%
+4,475,000
New +$14.9M
ENGN icon
39
enGene Therapeutics
ENGN
$126M
$12.3M 0.61%
+727,900
New +$8.91M
PRLD icon
40
Prelude Therapeutics
PRLD
$319M
$12.2M 0.6%
2,568,287
– –
ELVN icon
41
Enliven Therapeutics
ELVN
$3.73B
$11.8M 0.58%
671,358
+25,300
+4% +$388K
IOVA icon
42
Iovance Biotherapeutics
IOVA
$2.25B
$11.1M 0.55%
750,000
-650,000
-46% -$7.57M
JSPR icon
43
Jasper Therapeutics
JSPR
$27.3M
$10.3M 0.51%
+350,000
New +$6.22M
BOLD
44
Boundless Bio
BOLD
$55.7M
$10.1M 0.5%
+711,329
New +$10.1M
SYRE icon
45
Spyre Therapeutics
SYRE
$8.64B
$9.48M 0.47%
250,000
– –
IPSC icon
46
Century Therapeutics
IPSC
$399M
$7.32M 0.36%
+1,750,000
New +$7.41M
ZNTL icon
47
Zentalis Pharmaceuticals
ZNTL
$370M
$7.09M 0.35%
450,000
– –
AMLX icon
48
Amylyx Pharmaceuticals
AMLX
$1.99B
$4.26M 0.21%
+1,500,000
New +$19.6M
ABSI icon
49
Absci
ABSI
$1.39B
$3.98M 0.2%
+700,000
New +$3.15M
ATRA icon
50
Atara Biotherapeutics
ATRA
$75.4M
$2.88M 0.14%
+166,000
New +$2.95M
1
2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Boxer Capital held 65 positions worth $2.02B, up 0.92% from $2.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Boxer Capital withdrew a net $139M in Q1 2024, closing 6 positions and reducing 4 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $188M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Amylyx Pharmaceuticals worth $4.26M.

  • Boxer Capital's largest Q1 2024 buy was Amylyx Pharmaceuticals: 1,500,000 shares worth $4.26M.
  • Boxer Capital added most to Fate Therapeutics in Q1 2024, an estimated $47.8M increase.
  • Boxer Capital's biggest Q1 2024 reduction was argenx, cutting an estimated $23.2M.
  • Boxer Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $188M.
  • Boxer Capital's ten largest holdings make up 54% of its $2.02B portfolio in Q1 2024.
  • Boxer Capital opened 13 new positions and closed 6 in Q1 2024.
  • Boxer Capital's portfolio value rose 0.92% quarter-over-quarter to $2.02B.

Based on Boxer Capital's 13F filing for Q1 2024, filed 15 May 2024.